<DOC>
	<DOCNO>NCT00831493</DOCNO>
	<brief_summary>Primary Endpoint : To determine maximum tolerate dose ( MTD ) vorinostat + radiation therapy ( RT ) patient locally advanced pancreatic cancer ( LAPC ) . Secondary Endpoints : 1 . To assess efficacy vorinostat + RT patient LAPC estimate median overall survival . 2 . To determine radiological response assess regular computer tomography ( CT ) and/or dynamic contrast enhance computer tomography ( DCE-CT ) among patient treat vorinostat RT . 3 . To evaluate occurrence symptom correlate disease progression tolerance treatment use MD Anderson Symptom Inventory-Gastrointestinal Module ( MDASI-GI ) self-reporting tool . 4 . To correlate serum cytokine level symptoms treatment outcome .</brief_summary>
	<brief_title>Vorinostat Plus Radiation Therapy Pancreatic Cancer</brief_title>
	<detailed_description>The Study Drugs : Vorinostat design interfere growth cancer cell . Study Drug Dose Level : If find eligible take part study , begin receive vorinostat . The dose receive base many participant enrol , safety data available . The first group 3 enrol participant give low dos vorinostat . If intolerable side effect occur , next group 3 enrol high dose level . The study doctor tell dose receive compare dose participant receive . Up 3 dose level test . Study Drug Administration : On day receive radiation , take vorinostat ( capsule take mouth ) morning food . Radiation : You receive radiation day Monday Friday , except holiday . This schedule continue 5 1/2 week 28 dos total . Each radiation treatment usually last 10-15 minute . Surgical Evaluation : After complete radiation therapy , come back follow-up visit 6-12 week later . Length Study : You remain study 5 1/2 week . You take off-study early disease get bad intolerable side effect occur . This investigational study . Vorinostat FDA approve commercially available . The use vorinostat pancreatic cancer combination radiation investigational . At time , combination use research . Up 37 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 2 . Patients must &gt; /= 18 year age . There upper age restriction . 3 . Cytologic histologic proof adenocarcinoma pancreas . Patients tumor originate part pancreas . Islet cell tumor eligible . Only patient non metastatic , unresectable disease ( American Joint Committee Cancer ( AJCC ) 2002 stage T4 NX M0 ) eligible . Patients undergo resection underlie medical problem also eligible . Patients regional nodal disease eligible . 4 . All patient must stag physical exam , chest xray/CXR , contrastenhanced helical thincut abdominal CT. Unresectability define CT criterion : ) evidence tumor extension celiac axis superior mesenteric ( SM ) artery , b ) evidence either CT angiogram occlusion SM vein SM/ portal vein confluence . If tumor meet definition find unresectable surgical exploration , tumor consider unresectable . 5 . Patients may receive prior chemotherapy prior radiation therapy upper abdomen . 6 . Bone marrow function : absolute neutrophil count ( ANC ) &gt; 1,500/ul . Platelets &gt; 100,000/ul . 7 . Hepatic function : Total bilirubin less 1.5mg/dL . If patient require endobiliary stent and/or external biliary drain , bilirubin level must decline consecutive measurement indicate adequate biliary decompression ; alanine aminotransferase ( ALT ) &lt; /= 5 time upper limit normal . 8 . Renal function : Blood urea nitrogen ( BUN ) &lt; /= 30 mg % creatinine &lt; /= 1.5 mg % 9 . Patients must willing sign inform consent indicate aware investigational nature study , aware participation voluntary . 1 . Prior abdominal radiotherapy . 2 . Participation experimental drug study 30 day precede initiation treatment current study . 3 . Prior treatment HDAC inhibitor ( except valproic acid 30day washout period ) 4 . Prior history cancer within last five year except basal cell carcinoma skin carcinoma situ cervix . Patients previous malignancy without evidence disease 5 year allow enter trial . 5 . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline . Women / men childbearing potential use reliable contraceptive method ( oral contraceptive , hormonal contraceptive , intrauterine device , diaphragm condom ) . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Patients must agree continue contraception 30 day date last study drug administration . 6 . Serious , uncontrolled , concurrent infection ( ) require intravenous ( IV ) antibiotic nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy . 7 . Current treatment active hepatitis virus HIV infection interferon , ribavirin , telbivudine , entecavir , lamivudine , adefovir , efavirenz , zidovudine , tenofovir , emtricitabine , ritonavir . 8 . Psychiatric disorder render patient incapable comply requirement protocol . 9 . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Locally Advanced Pancreatic Cancer</keyword>
	<keyword>LAPC</keyword>
	<keyword>Non-Metastatic</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>XRT</keyword>
	<keyword>RT</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
</DOC>